ArticleBlood advances2024
Decreasing chronic graft-versus-host disease rates in all populations.
Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.Journal for immunotherapy of cancer · 2026Guideline
- The BIOPREVENT machine-learning algorithm predicts chronic graft-versus-host disease and mortality risk using posttransplant biomarkers.The Journal of clinical investigation · 2026Trial
- Trial
- GVHD prophylaxis and incidence in contemporary alloHSCT: a large real-world GETH/TC analysis.Bone marrow transplantation · 2026Article
- Shuffling the JAKs: playing a new card in chronic GVHD.Blood advances · 2026Article
- Plasma proteins associated with chronic graft-versus-host disease organ involvement.JCI insight · 2026Article
- Preemptive hematopoietic stem cell transplantation inHaematologica · 2026Article
- Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in Japan: changes in practice patterns and outcomes during the past 20 years.International journal of hematology · 2026Article
- Outcomes of patients with hematological malignancies complicated with autoimmune diseases after allogeneic hematopoietic stem cell transplantation: A ten-year real-world study.Journal of translational internal medicine · 2026Article
- Chronic graft-<I>versus</i>-host disease in the era of posttransplant cyclophosphamide.Haematologica · 2026Article
- Boosting "Treg-ulation": a good way to treat chronic GVHD?Blood advances · 2026Article
- Acute and Chronic Cutaneous Graft-versus-Host Disease: Diagnosis, Treatment, and Emerging Directions.American journal of clinical dermatology · 2026Review
- Discordance in Treatment Response Assessment Between Clinicians and Patients With Skin Chronic Graft-vs-Host Disease.JAMA dermatology · 2026Observational
- Chronic Graft-versus-Host disease trends over 30 years - a study by the EBMT transplant complications working party.Bone marrow transplantation · 2025Article
- Exhausted-like effector CD8 T cells mediate immune-stromal interactions at mucosal Chronic Graft-versus-Host Disease onset.bioRxiv : the preprint server for biology · 2025Article
- Oral Health Characteristics 2 Years following Allogeneic Cell Transplant.Journal of dental research · 2025Observational
- NIH Chronic Graft-Versus-Host Disease Consensus Conference 2025 Update.Transplantation and cellular therapy · 2025Review
- Reduced incidence of relapse and graft-Haematologica · 2025Article
- FDA-approved therapies for chronic GVHD.Blood · 2025Review
- Modern-Era Challenges in the Clinical Management of Graft-Versus-Host Disease.Advances in experimental medicine and biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
abstractSince 2005, there has been a steady decline in chronic graft-versus-host disease (cGVHD) at the Fred Hutchinson Cancer Center. To better understand this phenomenon, we studied the risk of cGVHD requiring systemic immunosuppression (cGVHD-IS) as a function of hematopoietic cell transplantation (HCT) date in 3066 survivors from 2005 through 2019. Cox regression models were fit to assess associations of HCT date (as a continuous linear variable) with cause-specific hazards of cGVHD using unadjusted and adjusted models. Median follow-up for study subjects was 7.0 years (range, 1.0-17.2). Two-year probabilities of cGVHD-IS declined among all survivors from 45% to 52% (2005-2007) to ∼40% (2008-2012) and then further to ∼26% by 2017. A decline was also observed when the analysis was restricted to 502 pediatric survivors, with cGVHD-IS probabilities <10% since 2013. Among 305 adult and pediatric survivors who underwent transplantation for nonmalignant diseases, cGVHD rates showed greater fluctuation but remained <20% after 2016. Each 5-year increase in HCT date was associated with a 27% decrease in the cause-specific hazard of cGVHD (unadjusted hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.68-0.78; P < .0001); the HR was 0.81 (95% CI, 0.75-0.87; P < .0001) even after adjusting for various factors (age, donor/stem-cell source, race, sex, conditioning intensity, GVHD prophylaxis, among others) that could lead to cGVHD reduction. The decline in cGVHD was not fully explained by demographic shifts and greater use of HCT approaches that are generally associated with lower cGVHD rates. This observation underscores that single-cohort cGVHD prevention studies should use contemporaneous and not historical controls for comparison.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.